Harvard Bioscience Inc
Harvard Bioscience, Inc. develops, manufactures, and sells technologies, products, and services for life science applications in the United States, Germany, and internationally. The company offers cellular and molecular technology products, such as syringe and peristaltic infusion pump products; electroporation and electrofusion instruments, amino acid analyzers, spectrophotometers, and other equ… Read more
Harvard Bioscience Inc (HBIO) - Net Assets
Latest net assets as of September 2025: $14.07 Million USD
Based on the latest financial reports, Harvard Bioscience Inc (HBIO) has net assets worth $14.07 Million USD as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($77.99 Million) and total liabilities ($63.92 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $14.07 Million |
| % of Total Assets | 18.04% |
| Annual Growth Rate | 19.06% |
| 5-Year Change | -17.4% |
| 10-Year Change | -18.37% |
| Growth Volatility | 229.25 |
Harvard Bioscience Inc - Net Assets Trend (1998–2024)
This chart illustrates how Harvard Bioscience Inc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Harvard Bioscience Inc (1998–2024)
The table below shows the annual net assets of Harvard Bioscience Inc from 1998 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $63.34 Million | -13.32% |
| 2023-12-31 | $73.07 Million | +1.18% |
| 2022-12-31 | $72.22 Million | -13.41% |
| 2021-12-31 | $83.40 Million | +8.76% |
| 2020-12-31 | $76.68 Million | -6.14% |
| 2019-12-31 | $81.69 Million | -0.60% |
| 2018-12-31 | $82.18 Million | +1.59% |
| 2017-12-31 | $80.90 Million | +12.06% |
| 2016-12-31 | $72.20 Million | -6.96% |
| 2015-12-31 | $77.60 Million | -18.72% |
| 2014-12-31 | $95.47 Million | +1.04% |
| 2013-12-31 | $94.48 Million | -9.33% |
| 2012-12-31 | $104.21 Million | +9.12% |
| 2011-12-31 | $95.50 Million | +5.82% |
| 2010-12-31 | $90.25 Million | +19.92% |
| 2009-12-31 | $75.26 Million | +12.80% |
| 2008-12-31 | $66.72 Million | -10.01% |
| 2007-12-31 | $74.14 Million | +3.14% |
| 2006-12-31 | $71.88 Million | +5.07% |
| 2005-12-31 | $68.42 Million | -34.44% |
| 2004-12-31 | $104.36 Million | +5.54% |
| 2003-12-31 | $98.88 Million | +11.88% |
| 2002-12-31 | $88.38 Million | +32.28% |
| 2001-12-31 | $66.81 Million | +27.66% |
| 2000-12-31 | $52.33 Million | +555.52% |
| 1999-12-31 | $7.98 Million | +1077.55% |
| 1998-12-31 | $678.00K | -- |
Equity Component Analysis
This analysis shows how different components contribute to Harvard Bioscience Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 15801000000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $441.00K | 0.70% |
| Other Comprehensive Income | $-15.67 Million | -24.74% |
| Other Components | $236.58 Million | 373.51% |
| Total Equity | $63.34 Million | 100.00% |
Harvard Bioscience Inc Competitors by Market Cap
The table below lists competitors of Harvard Bioscience Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
PetVivo Holdings Inc
NASDAQ:PETV
|
$24.80 Million |
|
PLAYMATES HLDGS NEW HD-10
F:PLJ2
|
$24.80 Million |
|
Tirathai Public Company Limited
BK:TRT
|
$24.81 Million |
|
Egeplast Ege Plastik Ticaret ve Sanayi AS
IS:EPLAS
|
$24.82 Million |
|
ZUE SA
WAR:ZUE
|
$24.79 Million |
|
Carma Limited
AU:CMA
|
$24.79 Million |
|
Grand-Tek Technology Co. Ltd.
TWO:3684
|
$24.79 Million |
|
Peak Resources Limited
PINK:PKREF
|
$24.79 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Harvard Bioscience Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 73,074,000 to 63,340,000, a change of -9,734,000 (-13.3%).
- Net loss of 12,405,000 reduced equity.
- Share repurchases of 577,000 reduced equity.
- Other comprehensive income decreased equity by 1,480,000.
- Other factors increased equity by 4,728,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-12.40 Million | -19.58% |
| Share Repurchases | $577.00K | -0.91% |
| Other Comprehensive Income | $-1.48 Million | -2.34% |
| Other Changes | $4.73 Million | +7.46% |
| Total Change | $- | -13.32% |
Book Value vs Market Value Analysis
This analysis compares Harvard Bioscience Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 3.35x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 40.21x to 3.35x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 1998-12-31 | $0.12 | $4.87 | x |
| 1999-12-31 | $1.43 | $4.87 | x |
| 2000-12-31 | $6.54 | $4.87 | x |
| 2001-12-31 | $2.59 | $4.87 | x |
| 2002-12-31 | $3.20 | $4.87 | x |
| 2003-12-31 | $3.22 | $4.87 | x |
| 2004-12-31 | $3.36 | $4.87 | x |
| 2005-12-31 | $2.22 | $4.87 | x |
| 2006-12-31 | $2.31 | $4.87 | x |
| 2007-12-31 | $2.36 | $4.87 | x |
| 2008-12-31 | $2.13 | $4.87 | x |
| 2009-12-31 | $2.51 | $4.87 | x |
| 2010-12-31 | $3.07 | $4.87 | x |
| 2011-12-31 | $3.20 | $4.87 | x |
| 2012-12-31 | $3.50 | $4.87 | x |
| 2013-12-31 | $2.96 | $4.87 | x |
| 2014-12-31 | $2.87 | $4.87 | x |
| 2015-12-31 | $2.31 | $4.87 | x |
| 2016-12-31 | $2.11 | $4.87 | x |
| 2017-12-31 | $2.33 | $4.87 | x |
| 2018-12-31 | $2.25 | $4.87 | x |
| 2019-12-31 | $2.16 | $4.87 | x |
| 2020-12-31 | $1.98 | $4.87 | x |
| 2021-12-31 | $2.07 | $4.87 | x |
| 2022-12-31 | $1.74 | $4.87 | x |
| 2023-12-31 | $1.72 | $4.87 | x |
| 2024-12-31 | $1.45 | $4.87 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Harvard Bioscience Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -19.58%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -13.18%
- • Asset Turnover: 0.74x
- • Equity Multiplier: 2.00x
- Recent ROE (-19.58%) is above the historical average (-20.55%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 1998 | 10.47% | 0.58% | 1.68x | 10.65x | $3.20K |
| 1999 | -368.50% | -112.38% | 1.27x | 2.58x | $-30.22 Million |
| 2000 | -95.29% | -163.11% | 0.52x | 1.12x | $-55.10 Million |
| 2001 | -7.80% | -12.74% | 0.50x | 1.23x | $-11.89 Million |
| 2002 | 0.83% | 1.28% | 0.53x | 1.22x | $-8.10 Million |
| 2003 | 4.31% | 4.89% | 0.68x | 1.30x | $-5.63 Million |
| 2004 | 2.23% | 2.52% | 0.66x | 1.34x | $-8.11 Million |
| 2005 | -46.59% | -47.27% | 0.73x | 1.35x | $-38.72 Million |
| 2006 | -3.26% | -3.07% | 0.82x | 1.30x | $-9.53 Million |
| 2007 | -1.83% | -1.62% | 0.84x | 1.33x | $-8.77 Million |
| 2008 | 2.51% | 1.90% | 1.08x | 1.22x | $-5.00 Million |
| 2009 | 9.61% | 8.43% | 0.80x | 1.42x | $-292.70K |
| 2010 | 21.07% | 17.58% | 0.87x | 1.38x | $9.99 Million |
| 2011 | 3.99% | 3.50% | 0.86x | 1.33x | $-5.74 Million |
| 2012 | 2.27% | 2.13% | 0.83x | 1.28x | $-8.05 Million |
| 2013 | -1.94% | -1.74% | 0.78x | 1.43x | $-11.28 Million |
| 2014 | 2.47% | 2.17% | 0.80x | 1.42x | $-7.19 Million |
| 2015 | -24.54% | -17.52% | 0.90x | 1.55x | $-26.80 Million |
| 2016 | -5.97% | -4.12% | 0.97x | 1.49x | $-11.53 Million |
| 2017 | -1.07% | -0.85% | 0.93x | 1.35x | $-8.96 Million |
| 2018 | -4.21% | -2.87% | 0.72x | 2.05x | $-11.68 Million |
| 2019 | -5.74% | -4.03% | 0.70x | 2.02x | $-12.86 Million |
| 2020 | -10.19% | -7.65% | 0.65x | 2.04x | $-15.48 Million |
| 2021 | -0.35% | -0.24% | 0.73x | 1.95x | $-8.63 Million |
| 2022 | -13.18% | -8.40% | 0.78x | 2.01x | $-16.74 Million |
| 2023 | -4.67% | -3.04% | 0.82x | 1.88x | $-10.72 Million |
| 2024 | -19.58% | -13.18% | 0.74x | 2.00x | $-18.74 Million |
Industry Comparison
This section compares Harvard Bioscience Inc's net assets metrics with peer companies in the Medical Instruments & Supplies industry.
Industry Context
- Industry: Medical Instruments & Supplies
- Average net assets among peers: $2,683,526,542
- Average return on equity (ROE) among peers: -32.48%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Harvard Bioscience Inc (HBIO) | $14.07 Million | 10.47% | 4.54x | $24.80 Million |
| ANGELALIGN TECHNOLOGY INC (AGLFF) | $480.24 Million | 2.52% | 0.41x | $405.57 Million |
| Akoya Biosciences Inc (AKYA) | $-30.16 Million | 0.00% | 0.00x | $16.24 Million |
| Alcon AG (ALC) | $19.68 Billion | 1.70% | 0.48x | $37.82 Billion |
| Align Technology Inc (ALGN) | $3.85 Billion | 10.94% | 0.61x | $11.75 Billion |
| AngioDynamics Inc (ANGO) | $355.71 Million | 3.06% | 0.15x | $354.40 Million |
| Ansell Limited (ANSLF) | $386.33 Million | -0.45% | 0.87x | $2.58 Billion |
| AptarGroup Inc (ATR) | $2.07 Billion | 11.57% | 1.03x | $8.27 Billion |
| AtriCure Inc (ATRC) | $72.60 Million | -15.79% | 0.54x | $1.42 Billion |
| Avinger Inc (AVGR) | $-35.69 Million | 0.00% | 0.00x | $1.26 Million |
| Anteris Technologies Global Corp. Common Stock (AVR) | $9.03 Million | -338.35% | 0.77x | $156.14 Million |